BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 22271250)

  • 1. A model for dropout assessment of candidates with or without hepatocellular carcinoma on a common liver transplant waiting list.
    Toso C; Dupuis-Lozeron E; Majno P; Berney T; Kneteman NM; Perneger T; Morel P; Mentha G; Combescure C
    Hepatology; 2012 Jul; 56(1):149-56. PubMed ID: 22271250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liver transplantation in septuagenarians receiving model for end-stage liver disease exception points for hepatocellular carcinoma: the national experience.
    Schwartz JJ; Pappas L; Thiesset HF; Vargas G; Sorensen JB; Kim RD; Hutson WR; Boucher K; Box T
    Liver Transpl; 2012 Apr; 18(4):423-33. PubMed ID: 22250078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new priority policy for patients with hepatocellular carcinoma awaiting liver transplantation within the model for end-stage liver disease system.
    Piscaglia F; Camaggi V; Ravaioli M; Grazi GL; Zanello M; Leoni S; Ballardini G; Cavrini G; Pinna AD; Bolondi L
    Liver Transpl; 2007 Jun; 13(6):857-66. PubMed ID: 17539006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A method for establishing allocation equity among patients with and without hepatocellular carcinoma on a common liver transplant waiting list.
    Vitale A; Volk ML; De Feo TM; Burra P; Frigo AC; Ramirez Morales R; De Carlis L; Belli L; Colledan M; Fagiuoli S; Rossi G; Andorno E; Baccarani U; Regalia E; Vivarelli M; Donataccio M; Cillo U;
    J Hepatol; 2014 Feb; 60(2):290-7. PubMed ID: 24161408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MELDEQ : An alternative Model for End-Stage Liver Disease score for patients with hepatocellular carcinoma.
    Marvin MR; Ferguson N; Cannon RM; Jones CM; Brock GN
    Liver Transpl; 2015 May; 21(5):612-22. PubMed ID: 25694099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of a dropout assessment model of candidates with/without hepatocellular carcinoma on a common liver transplant waiting list.
    Toso C; Majno P; Berney T; Morel P; Mentha G; Combescure C
    Transpl Int; 2014 Jul; 27(7):686-95. PubMed ID: 24649861
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liver transplantation for hepatocellular carcinoma: the MELD impact.
    Sharma P; Balan V; Hernandez JL; Harper AM; Edwards EB; Rodriguez-Luna H; Byrne T; Vargas HE; Mulligan D; Rakela J; Wiesner RH
    Liver Transpl; 2004 Jan; 10(1):36-41. PubMed ID: 14755775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An analysis of the UNOS liver transplant registry: high serum alpha-fetoprotein does not justify an increase in MELD points for suspected hepatocellular carcinoma.
    Kemmer N; Neff G; Kaiser T; Zacharias V; Thomas M; Tevar A; Satwah S; Shukla R; Buell J
    Liver Transpl; 2006 Oct; 12(10):1519-22. PubMed ID: 17004260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liver transplantation for hepatocellular carcinoma: impact of the MELD allocation system and predictors of survival.
    Ioannou GN; Perkins JD; Carithers RL
    Gastroenterology; 2008 May; 134(5):1342-51. PubMed ID: 18471511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The model for end-stage liver disease score is the best prognostic factor in human immunodeficiency virus 1-infected patients with end-stage liver disease: a prospective cohort study.
    Murillas J; Rimola A; Laguno M; de Lazzari E; Rascón J; Agüero F; Blanco JL; Moitinho E; Moreno A; Miró JM;
    Liver Transpl; 2009 Sep; 15(9):1133-41. PubMed ID: 19718643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liver transplantation for hepatocellular carcinoma: lessons from the first year under the Model of End-Stage Liver Disease (MELD) organ allocation policy.
    Yao FY; Bass NM; Ascher NL; Roberts JP
    Liver Transpl; 2004 May; 10(5):621-30. PubMed ID: 15108253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Model for End-Stage Liver Disease (MELD) system to allocate and to share livers: experience of two Italian centers.
    Ravaioli M; Masetti M; Dazzi A; Romano A; Spaggiari M; Grazi GL; Ercolani G; Cescon M; Di Gioia P; De Ruvo N; Montalti R; Ballarin R; Di Benedetto F; Ridolfi L; Alvaro N; Ramacciato G; Morelli C; Gerunda E; Pinna AD
    Transplant Proc; 2008; 40(6):1814-5. PubMed ID: 18675057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Consequences of the implementation of the Model for End-stage Liver Disease system for liver allocation in Brazil.
    Pestana RC; Baracat EI; Massarollo PC; Pereira LA; Szutan LA
    Transplant Proc; 2013; 45(6):2111-4. PubMed ID: 23747144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allocation policy for hepatocellular carcinoma in the MELD era: room for improvement?
    Roayaie K; Feng S
    Liver Transpl; 2007 Nov; 13(11 Suppl 2):S36-43. PubMed ID: 17969067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Model for End-Stage Liver Disease (MELD) score system to evaluate patients with viral hepatitis on the waiting list: better than the Child-Turcotte-Pugh (CTP) system?
    Cuomo O; Perrella A; Arenga G
    Transplant Proc; 2008; 40(6):1906-9. PubMed ID: 18675085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A follow-up analysis of the pattern and predictors of dropout from the waiting list for liver transplantation in patients with hepatocellular carcinoma: implications for the current organ allocation policy.
    Yao FY; Bass NM; Nikolai B; Merriman R; Davern TJ; Kerlan R; Ascher NL; Roberts JP
    Liver Transpl; 2003 Jul; 9(7):684-92. PubMed ID: 12827553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Priority of candidates with hepatocellular carcinoma awaiting liver transplantation can be reduced after successful bridge therapy.
    Cucchetti A; Cescon M; Bigonzi E; Piscaglia F; Golfieri R; Ercolani G; Cristina Morelli M; Ravaioli M; Daniele Pinna A
    Liver Transpl; 2011 Nov; 17(11):1344-54. PubMed ID: 21837731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An intention-to-treat analysis of liver transplantation for hepatocellular carcinoma using organ procurement transplant network data.
    Pelletier SJ; Fu S; Thyagarajan V; Romero-Marrero C; Batheja MJ; Punch JD; Magee JC; Lok AS; Fontana RJ; Marrero JA
    Liver Transpl; 2009 Aug; 15(8):859-68. PubMed ID: 19642139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liver transplantation in the MELD era--analysis of the OPTN/UNOS registry.
    Taniguchi M
    Clin Transpl; 2012; ():41-65. PubMed ID: 23721009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival benefit after liver transplantation: a single European center experience.
    Ravaioli M; Grazi GL; Dazzi A; Bertuzzo V; Ercolani G; Cescon M; Cucchetti A; Masetti M; Ramacciato G; Pinna AD
    Transplantation; 2009 Sep; 88(6):826-34. PubMed ID: 19920783
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.